Beaker
Beaker.com
Presented by     presented by Beaker.com
AdvaMed 2012: The MedTech Conference calls for presentations
Jeffrey Clark - Posted: 1/27/2012
The premier medical device and technology event of the year, AdvaMed 2012: The MedTech Conference has officially launched its new website and opened the call for program panel proposals. Annually one of the strongest events of the year, Advamed 2012 [...]
The End of Illness: Devices That Could Change Medical Care
Jeffrey Clark - Posted: 1/25/2012
Dr. David Agus, the former oncologist for the late Steve Jobs, is all over the news, following the release of his book The End of Illness last month According to Agus, we can do better analyzing the human body and using more advanced technologies to [...]
Illumina corporate structure moves Roche to checkmate
Jeffrey Clark - Posted: 1/25/2012
With a poison pill provision and staggered Board elections, Illumina seems to be well-protected from unruly suitors during a time when its stock price is so undervalued.  So, how will Roche win the chess match with Illuminas Board and its shareholder[...]
Roches deal for Illumina a potential boon for San Diego, hurts Indy
Jeffrey Clark - Posted: 1/25/2012
Roche has its sights set on Illumina, the San Diego based sequencing company.  Roche CEO Severin Schwan has repeatedly emphasized the the need for new and better targeted drugs.  Illumina would complement Roche beautifully both with Genentechs focus[...]
President Obama on FDA regulatory structure, in plain English
Jeffrey Clark - Posted: 1/24/2012
Just days ago, President Obama authored an article in the Wall Street Journal entitled, Toward a 21st-Century Regulatory System. While not wholly specific to the life sciences industry, he does address government regulatory process in general as inef[...]
Sanofi CEO speaks out toward FDA on behalf of PhRMA
Jeffrey Clark - Posted: 1/24/2012
Chris Viehbacher has become an outspoken voice since taking the helm at chairman of the board for PhRMA.   His latest comments are aimed at the FDA, claiming that the pharmaceutical industry may stop investing in medicines to treat diseases like diab[...]
Inside Boston Scientifics CEO Transition
Jeffrey Clark - Posted: 1/23/2012
Hank Kucheman, Boston Scientific Interim CEO, and Michael Mahoney, Boston Scientific Icoming CEO, shed insight on a pro-longed CEO transition and pricing pressures in the device industry. Remember that Mahoney was the Group Chairman of J&Js Medical D[...]
Alkermes and Amylin come down to the wire
Jeffrey Clark - Posted: 1/20/2012
Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates. These are nervous times at Alkermes and Amylin. Bydureon is a long-[...]
FDAs User Fee Agreement heads to Congress
Jeffrey Clark - Posted: 1/19/2012
A final agreement between the FDA and the pharmaceutical industry on user fees for prescription, generic and biosimilar drugs was submitted for approval by Congress. At a time of greater budgetary constraint, user fees provide a critical way for leve[...]
Report: Medtech market in China to reach $5 billion this year
Jeffrey Clark - Posted: 1/18/2012
The medical device market in China will rise 17% to $5 billion this year, according to a report from Citigroup.   Chinas growth is no secret, yet medical device spending will be boosted by growing demand from hospitals as they modernize and improve t[...]
Johnson and Johnson CEO opines on the state of healthcare, economy
Jeffrey Clark - Posted: 1/17/2012
We are seeing a slow recovery in the U.S. and while there are challenges there are opportunities to take advantage of the slow recovery, says William Weldon, Johnson & Johnson chairman/CEO.
Seattle life sciences companies ready for massive snowstorm
Jeffrey Clark - Posted: 1/17/2012
Rarely is weather a big topic on Beaker.  In fact, places like Chicago, Minneapolis and Boston may not blink in the face of 12-18 inches of snow in January. But for Seattle, what is set to unfold is being described as a crippling blizzard that will b[...]
Baxter recruits key executive from Medtronic
Jeffrey Clark - Posted: 1/17/2012
Baxter International has recruited a key member of Medtronic CEO Omar Ishraks team.   Jean-Luc Butel has been appointed Corporate VP & President, International reporting to Robert L. Parkinson, Jr., Chairman and CEO at Baxter. Butel, 55, will be resp[...]
Celgene & Gilead CEOs review earnings, emerging markets, and more
Jeffrey Clark - Posted: 1/16/2012
Gilead Sciences makes a big move into hepatitis C treatment with its acquisition of Pharmasset. Insight with John Martin, Gilead Sciences CEO/president. Robert Hugin, Celgene chairman & CEO, explains why Celgenes 2012 earnings will top expectations o[...]
Vertex & Biogen CEOs Talk Business
Jeffrey Clark - Posted: 1/16/2012
Jeffrey Leiden, incoming CEO of Vertex Pharmaceuticals, and George Scangos, CEO of Biogen Idec, discuss Biogens restructuring and Vertexs Hepatitis C drug.
Medical Device Titans on Obamacare, excise tax and JPM12
Jeffrey Clark - Posted: 1/13/2012
CEOs of Stryker, Medtronic and Edwards Life Sciences make a joint appearance to discuss how Obamacares new 2.3% tax on the biggest medical device makers is impacting business. This has to be the first time these guys have shared a panel: Omar Ishrak,[...]
Onyx, Seattle Genetics and Dendreon CEOs predict outlook at JPM12
Jeffrey Clark - Posted: 1/13/2012
Dr. Tony Coles, President & CEO of Onyx Pharmaceuticals, discusses his outlook for the new year. Dendreons revenues for its solo product, Provenge, has more than tripled from a year ago. Insight on the drugs treatment of prostate cancer and an outloo[...]
Sanofi CEO talks patent cliffs and potato chips at JPM12
Jeffrey Clark - Posted: 1/12/2012
Chris Viehbacher, CEO of Sanofi-Aventis, comments on the upcoming Plavix patent cliff, potential acquisitions in 2012, the Sanofi dividend, emerging markets and his now infamous comments about soda & potato chip companies.
Best tweets and quotes from #JPM12
Jeffrey Clark - Posted: 1/11/2012
Best Quotes from JP Morgan Healthcare Conference Gators appear when you drain the swamp.  new CEO of Hospira Michael Ball (formerly of Allergan) on the quality issues the company is managing at one of its production facilities.  Ball calls Hospiras p[...]
Novartis recall has potentially scary but unlikely outcome
Jeffrey Clark - Posted: 1/11/2012
The FDA  is warning patients about a potential mix-up between powerful prescription pain drugs and common over-the-counter medications made at a Novartis manufacturing plant in Lincoln, Nebraska. The issue stems from manufacturing problems which trig[...]
The Super Bowl of the life sciences industry underway
Jeffrey Clark - Posted: 1/10/2012
The Super Bowl may be still weeks away, but the life sciences is hosting its own annual version this week in California. The JP Morgan Healthcare Conference officially started Monday, for the 30th consecutive year. If you’ve never been, the conferenc[...]
Raleigh Durham to host big-name CEOs
Jeffrey Clark - Posted: 1/10/2012
On the heels of the JP Morgan Healthcare Conference in California, the state of North Carolina will host the CED Life Sciences conference hosted in partnership with the North Carolina Biotechnology Center and NC Biosciences Organization. While region[...]
Cool Technology: Smith and Nephew introduces PICO
Jeffrey Clark - Posted: 1/9/2012
Smith & Nephew is marketing its new PICO product as an entirely new way to deliver Negative Pressure Wound Therapy (NPWT). The product was just approved by the FDA in the US and is already sold in several overseas markets. NPWT promotes wound healing[...]
FDA approvals up in 2011. Will the trend continue?
Jeffrey Clark - Posted: 1/9/2012
FDA approvals of new drugs hit a seven-year high in 2011 with 30 new treatments approved, compared to just 21 approvals in 2010. The increase is attributed to pharmaceutical companies responding to regulators’ demands for better safety data. Johnson [...]
Stem Cell Fraud: A 60 Minutes investigation
Jeffrey Clark - Posted: 1/9/2012
60 Minutes chronicles stem cell fraud with a story of sketchy doctors offering fraudulent claims of near miraculous health improvements and cures from stem cell injections.
 
Beaker.com
BeakerBeat - 01-23-12
In this week’s BeakerBeat, to quote Rodney King, ”Can't we all just get along”?. Apparently they ca[...]
BeakerBeat - 01-16-12
In this week’s BeakerBeat, industry heavyweights attend the annual JP Morgan conference in San Franc[...]
BeakerBeat - 01-09-12
In this week’s BeakerBeat, it’s not as fun as a fantasy sports draft, but the FDA releases more draf[...]
BeakerBeat - 01-04-12
In this week’s BeakerBeat, while Santa stuffed stockings and Baby New Year arrived, much of the life[...]
BeakerBeat - 12-19-11
In this week’s BeakerBeat, ‘tis the season to be jolly, and that’s how one life sciences company is [...]